Loading…

Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats

The inflamed mucosa in ulcerative colitis produces high amount of prostaglandin (PG) and nitric oxide (NO) through inducible enzymes: cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), respectively, implicating them as potential anti-inflammatory drug targets. COX-2 or iNOS-related...

Full description

Saved in:
Bibliographic Details
Published in:Inflammopharmacology 2007-10, Vol.15 (5), p.188-195
Main Authors: Dudhgaonkar, S P, Tandan, S K, Kumar, D, Raviprakash, V, Kataria, M
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c311t-3e964714080b09b40667139a66d8bb80717ebc4e7eb04016b566a1b30bf3c8b33
cites
container_end_page 195
container_issue 5
container_start_page 188
container_title Inflammopharmacology
container_volume 15
creator Dudhgaonkar, S P
Tandan, S K
Kumar, D
Raviprakash, V
Kataria, M
description The inflamed mucosa in ulcerative colitis produces high amount of prostaglandin (PG) and nitric oxide (NO) through inducible enzymes: cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), respectively, implicating them as potential anti-inflammatory drug targets. COX-2 or iNOS-related treatments in different models of colitis have yielded ambiguous results ranging from exacerbation of disease to abolition of inflammation. iNOS and COX-2 induction is blocked by potent anti-inflammatory glucocorticoids, however, serious side effects including relapses limit their usefulness in colitis for long time. Simultaneous inhibition of iNOS and COX-2 was investigated in the current study in 2, 4, 6 trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. Treatment group received rofecoxib, aminoguanidine hydrochloride or their combination at different doses at 48, 36, 24, 12 and 1 h prior to induction of colitis and 12 h later. Colonic myeloperoxidase (MPO), COX-2, nitrate and nitrite, tumor necrosis factor-alpha (TNF-alpha) and lipid peroxidation were maximally reduced by combination of 10 mg/kg rofecoxib and 30 mg/kg of aminoguanidine hydrochloride in TNBS-induced colitis in rats. However, maximum increase in SOD and catalase was noted by this combination. Rats treated with rofecoxib, aminoguanidine hydrochloride and their combinations reduced the inflammation, acute colonic damage produced by TNBS as verified by macroscopic changes in colon. Combination of rofecoxib (10 mg/kg) and aminoguanidine hydrochloride (30 mg/kg) has maximal protective effect on colonic injury induced by TNBS enema which is probably, via mechanism of local inhibition of iNOS and COX-2 activity in colonic mucosa and support the idea that simultaneous inhibition of iNOS and COX-2 inhibitors have a promising potential in the treatment of colitis.
doi_str_mv 10.1007/s10787-007-1603-3
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20600767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20600767</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-3e964714080b09b40667139a66d8bb80717ebc4e7eb04016b566a1b30bf3c8b33</originalsourceid><addsrcrecordid>eNpFkE1LxDAQhoMouq7-AC-Sk7fopGmT9ijiFwhe9FySdOpGssnatLAL_nhTdsFLZmDePMw8hFxxuOUA6i5xULViuWVcgmDiiCx4JWtWSaiPyQKaomKlbIozcp7SNwBIJZtTcsZVU4qiggX5fQ29nzBYpLGnya0nP-qAcUrUhZUzbnQxzCO7sz7G7e4Lg07ICqpDlyPdZJ3xSIMbB2dp3LoOadqFcZVTeU5xu8HBrTGM2lMbfQbOaDroMV2Qk177hJeHuiSfT48fDy_s7f359eH-jVnB-cgENrJUvIQaDDSmBCkVF42WsquNqUFxhcaWmF8ogUtTSam5EWB6YWsjxJLc7LmbIf5MmMZ27ZJF7_eXtgXI7FCqHOT7oB1iSgP27Sbvroddy6Gdlbd75e3czsrbGX59gE9mjd3_j4Nj8Qe0wX5Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20600767</pqid></control><display><type>article</type><title>Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats</title><source>Springer Nature</source><creator>Dudhgaonkar, S P ; Tandan, S K ; Kumar, D ; Raviprakash, V ; Kataria, M</creator><creatorcontrib>Dudhgaonkar, S P ; Tandan, S K ; Kumar, D ; Raviprakash, V ; Kataria, M</creatorcontrib><description>The inflamed mucosa in ulcerative colitis produces high amount of prostaglandin (PG) and nitric oxide (NO) through inducible enzymes: cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), respectively, implicating them as potential anti-inflammatory drug targets. COX-2 or iNOS-related treatments in different models of colitis have yielded ambiguous results ranging from exacerbation of disease to abolition of inflammation. iNOS and COX-2 induction is blocked by potent anti-inflammatory glucocorticoids, however, serious side effects including relapses limit their usefulness in colitis for long time. Simultaneous inhibition of iNOS and COX-2 was investigated in the current study in 2, 4, 6 trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. Treatment group received rofecoxib, aminoguanidine hydrochloride or their combination at different doses at 48, 36, 24, 12 and 1 h prior to induction of colitis and 12 h later. Colonic myeloperoxidase (MPO), COX-2, nitrate and nitrite, tumor necrosis factor-alpha (TNF-alpha) and lipid peroxidation were maximally reduced by combination of 10 mg/kg rofecoxib and 30 mg/kg of aminoguanidine hydrochloride in TNBS-induced colitis in rats. However, maximum increase in SOD and catalase was noted by this combination. Rats treated with rofecoxib, aminoguanidine hydrochloride and their combinations reduced the inflammation, acute colonic damage produced by TNBS as verified by macroscopic changes in colon. Combination of rofecoxib (10 mg/kg) and aminoguanidine hydrochloride (30 mg/kg) has maximal protective effect on colonic injury induced by TNBS enema which is probably, via mechanism of local inhibition of iNOS and COX-2 activity in colonic mucosa and support the idea that simultaneous inhibition of iNOS and COX-2 inhibitors have a promising potential in the treatment of colitis.</description><identifier>ISSN: 0925-4692</identifier><identifier>EISSN: 1568-5608</identifier><identifier>DOI: 10.1007/s10787-007-1603-3</identifier><identifier>PMID: 17943250</identifier><language>eng</language><publisher>Switzerland</publisher><subject>Animals ; Catalase - metabolism ; Colitis - chemically induced ; Colitis - pathology ; Colitis - prevention &amp; control ; Colon - drug effects ; Colon - metabolism ; Colon - pathology ; Cyclooxygenase 2 - metabolism ; Cyclooxygenase 2 Inhibitors - pharmacology ; Cyclooxygenase 2 Inhibitors - therapeutic use ; Drug Therapy, Combination ; Enzyme Inhibitors - pharmacology ; Enzyme Inhibitors - therapeutic use ; Guanidines - pharmacology ; Guanidines - therapeutic use ; Intestine, Large - drug effects ; Intestine, Large - metabolism ; Intestine, Large - pathology ; Lactones - pharmacology ; Lactones - therapeutic use ; Lipid Peroxidation - drug effects ; Male ; Nitrates - metabolism ; Nitric Oxide Synthase Type II - antagonists &amp; inhibitors ; Nitrites - metabolism ; Peroxidase - metabolism ; Rats ; Rats, Inbred Strains ; Sulfones - pharmacology ; Sulfones - therapeutic use ; Superoxide Dismutase - metabolism ; Trinitrobenzenesulfonic Acid - toxicity ; Tumor Necrosis Factor-alpha - metabolism</subject><ispartof>Inflammopharmacology, 2007-10, Vol.15 (5), p.188-195</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-3e964714080b09b40667139a66d8bb80717ebc4e7eb04016b566a1b30bf3c8b33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17943250$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dudhgaonkar, S P</creatorcontrib><creatorcontrib>Tandan, S K</creatorcontrib><creatorcontrib>Kumar, D</creatorcontrib><creatorcontrib>Raviprakash, V</creatorcontrib><creatorcontrib>Kataria, M</creatorcontrib><title>Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats</title><title>Inflammopharmacology</title><addtitle>Inflammopharmacology</addtitle><description>The inflamed mucosa in ulcerative colitis produces high amount of prostaglandin (PG) and nitric oxide (NO) through inducible enzymes: cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), respectively, implicating them as potential anti-inflammatory drug targets. COX-2 or iNOS-related treatments in different models of colitis have yielded ambiguous results ranging from exacerbation of disease to abolition of inflammation. iNOS and COX-2 induction is blocked by potent anti-inflammatory glucocorticoids, however, serious side effects including relapses limit their usefulness in colitis for long time. Simultaneous inhibition of iNOS and COX-2 was investigated in the current study in 2, 4, 6 trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. Treatment group received rofecoxib, aminoguanidine hydrochloride or their combination at different doses at 48, 36, 24, 12 and 1 h prior to induction of colitis and 12 h later. Colonic myeloperoxidase (MPO), COX-2, nitrate and nitrite, tumor necrosis factor-alpha (TNF-alpha) and lipid peroxidation were maximally reduced by combination of 10 mg/kg rofecoxib and 30 mg/kg of aminoguanidine hydrochloride in TNBS-induced colitis in rats. However, maximum increase in SOD and catalase was noted by this combination. Rats treated with rofecoxib, aminoguanidine hydrochloride and their combinations reduced the inflammation, acute colonic damage produced by TNBS as verified by macroscopic changes in colon. Combination of rofecoxib (10 mg/kg) and aminoguanidine hydrochloride (30 mg/kg) has maximal protective effect on colonic injury induced by TNBS enema which is probably, via mechanism of local inhibition of iNOS and COX-2 activity in colonic mucosa and support the idea that simultaneous inhibition of iNOS and COX-2 inhibitors have a promising potential in the treatment of colitis.</description><subject>Animals</subject><subject>Catalase - metabolism</subject><subject>Colitis - chemically induced</subject><subject>Colitis - pathology</subject><subject>Colitis - prevention &amp; control</subject><subject>Colon - drug effects</subject><subject>Colon - metabolism</subject><subject>Colon - pathology</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>Cyclooxygenase 2 Inhibitors - pharmacology</subject><subject>Cyclooxygenase 2 Inhibitors - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Guanidines - pharmacology</subject><subject>Guanidines - therapeutic use</subject><subject>Intestine, Large - drug effects</subject><subject>Intestine, Large - metabolism</subject><subject>Intestine, Large - pathology</subject><subject>Lactones - pharmacology</subject><subject>Lactones - therapeutic use</subject><subject>Lipid Peroxidation - drug effects</subject><subject>Male</subject><subject>Nitrates - metabolism</subject><subject>Nitric Oxide Synthase Type II - antagonists &amp; inhibitors</subject><subject>Nitrites - metabolism</subject><subject>Peroxidase - metabolism</subject><subject>Rats</subject><subject>Rats, Inbred Strains</subject><subject>Sulfones - pharmacology</subject><subject>Sulfones - therapeutic use</subject><subject>Superoxide Dismutase - metabolism</subject><subject>Trinitrobenzenesulfonic Acid - toxicity</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><issn>0925-4692</issn><issn>1568-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNpFkE1LxDAQhoMouq7-AC-Sk7fopGmT9ijiFwhe9FySdOpGssnatLAL_nhTdsFLZmDePMw8hFxxuOUA6i5xULViuWVcgmDiiCx4JWtWSaiPyQKaomKlbIozcp7SNwBIJZtTcsZVU4qiggX5fQ29nzBYpLGnya0nP-qAcUrUhZUzbnQxzCO7sz7G7e4Lg07ICqpDlyPdZJ3xSIMbB2dp3LoOadqFcZVTeU5xu8HBrTGM2lMbfQbOaDroMV2Qk177hJeHuiSfT48fDy_s7f359eH-jVnB-cgENrJUvIQaDDSmBCkVF42WsquNqUFxhcaWmF8ogUtTSam5EWB6YWsjxJLc7LmbIf5MmMZ27ZJF7_eXtgXI7FCqHOT7oB1iSgP27Sbvroddy6Gdlbd75e3czsrbGX59gE9mjd3_j4Nj8Qe0wX5Q</recordid><startdate>200710</startdate><enddate>200710</enddate><creator>Dudhgaonkar, S P</creator><creator>Tandan, S K</creator><creator>Kumar, D</creator><creator>Raviprakash, V</creator><creator>Kataria, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>200710</creationdate><title>Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats</title><author>Dudhgaonkar, S P ; Tandan, S K ; Kumar, D ; Raviprakash, V ; Kataria, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-3e964714080b09b40667139a66d8bb80717ebc4e7eb04016b566a1b30bf3c8b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Catalase - metabolism</topic><topic>Colitis - chemically induced</topic><topic>Colitis - pathology</topic><topic>Colitis - prevention &amp; control</topic><topic>Colon - drug effects</topic><topic>Colon - metabolism</topic><topic>Colon - pathology</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>Cyclooxygenase 2 Inhibitors - pharmacology</topic><topic>Cyclooxygenase 2 Inhibitors - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Guanidines - pharmacology</topic><topic>Guanidines - therapeutic use</topic><topic>Intestine, Large - drug effects</topic><topic>Intestine, Large - metabolism</topic><topic>Intestine, Large - pathology</topic><topic>Lactones - pharmacology</topic><topic>Lactones - therapeutic use</topic><topic>Lipid Peroxidation - drug effects</topic><topic>Male</topic><topic>Nitrates - metabolism</topic><topic>Nitric Oxide Synthase Type II - antagonists &amp; inhibitors</topic><topic>Nitrites - metabolism</topic><topic>Peroxidase - metabolism</topic><topic>Rats</topic><topic>Rats, Inbred Strains</topic><topic>Sulfones - pharmacology</topic><topic>Sulfones - therapeutic use</topic><topic>Superoxide Dismutase - metabolism</topic><topic>Trinitrobenzenesulfonic Acid - toxicity</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dudhgaonkar, S P</creatorcontrib><creatorcontrib>Tandan, S K</creatorcontrib><creatorcontrib>Kumar, D</creatorcontrib><creatorcontrib>Raviprakash, V</creatorcontrib><creatorcontrib>Kataria, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Inflammopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dudhgaonkar, S P</au><au>Tandan, S K</au><au>Kumar, D</au><au>Raviprakash, V</au><au>Kataria, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats</atitle><jtitle>Inflammopharmacology</jtitle><addtitle>Inflammopharmacology</addtitle><date>2007-10</date><risdate>2007</risdate><volume>15</volume><issue>5</issue><spage>188</spage><epage>195</epage><pages>188-195</pages><issn>0925-4692</issn><eissn>1568-5608</eissn><abstract>The inflamed mucosa in ulcerative colitis produces high amount of prostaglandin (PG) and nitric oxide (NO) through inducible enzymes: cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), respectively, implicating them as potential anti-inflammatory drug targets. COX-2 or iNOS-related treatments in different models of colitis have yielded ambiguous results ranging from exacerbation of disease to abolition of inflammation. iNOS and COX-2 induction is blocked by potent anti-inflammatory glucocorticoids, however, serious side effects including relapses limit their usefulness in colitis for long time. Simultaneous inhibition of iNOS and COX-2 was investigated in the current study in 2, 4, 6 trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. Treatment group received rofecoxib, aminoguanidine hydrochloride or their combination at different doses at 48, 36, 24, 12 and 1 h prior to induction of colitis and 12 h later. Colonic myeloperoxidase (MPO), COX-2, nitrate and nitrite, tumor necrosis factor-alpha (TNF-alpha) and lipid peroxidation were maximally reduced by combination of 10 mg/kg rofecoxib and 30 mg/kg of aminoguanidine hydrochloride in TNBS-induced colitis in rats. However, maximum increase in SOD and catalase was noted by this combination. Rats treated with rofecoxib, aminoguanidine hydrochloride and their combinations reduced the inflammation, acute colonic damage produced by TNBS as verified by macroscopic changes in colon. Combination of rofecoxib (10 mg/kg) and aminoguanidine hydrochloride (30 mg/kg) has maximal protective effect on colonic injury induced by TNBS enema which is probably, via mechanism of local inhibition of iNOS and COX-2 activity in colonic mucosa and support the idea that simultaneous inhibition of iNOS and COX-2 inhibitors have a promising potential in the treatment of colitis.</abstract><cop>Switzerland</cop><pmid>17943250</pmid><doi>10.1007/s10787-007-1603-3</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0925-4692
ispartof Inflammopharmacology, 2007-10, Vol.15 (5), p.188-195
issn 0925-4692
1568-5608
language eng
recordid cdi_proquest_miscellaneous_20600767
source Springer Nature
subjects Animals
Catalase - metabolism
Colitis - chemically induced
Colitis - pathology
Colitis - prevention & control
Colon - drug effects
Colon - metabolism
Colon - pathology
Cyclooxygenase 2 - metabolism
Cyclooxygenase 2 Inhibitors - pharmacology
Cyclooxygenase 2 Inhibitors - therapeutic use
Drug Therapy, Combination
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Guanidines - pharmacology
Guanidines - therapeutic use
Intestine, Large - drug effects
Intestine, Large - metabolism
Intestine, Large - pathology
Lactones - pharmacology
Lactones - therapeutic use
Lipid Peroxidation - drug effects
Male
Nitrates - metabolism
Nitric Oxide Synthase Type II - antagonists & inhibitors
Nitrites - metabolism
Peroxidase - metabolism
Rats
Rats, Inbred Strains
Sulfones - pharmacology
Sulfones - therapeutic use
Superoxide Dismutase - metabolism
Trinitrobenzenesulfonic Acid - toxicity
Tumor Necrosis Factor-alpha - metabolism
title Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T23%3A15%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20simultaneous%20inhibition%20of%20cyclooxygenase-2%20and%20inducible%20nitric%20oxide%20synthase%20in%20experimental%20colitis%20in%20rats&rft.jtitle=Inflammopharmacology&rft.au=Dudhgaonkar,%20S%20P&rft.date=2007-10&rft.volume=15&rft.issue=5&rft.spage=188&rft.epage=195&rft.pages=188-195&rft.issn=0925-4692&rft.eissn=1568-5608&rft_id=info:doi/10.1007/s10787-007-1603-3&rft_dat=%3Cproquest_cross%3E20600767%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-3e964714080b09b40667139a66d8bb80717ebc4e7eb04016b566a1b30bf3c8b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20600767&rft_id=info:pmid/17943250&rfr_iscdi=true